eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2024
vol. 10
 
Share:
Send email
Share:
abstract:
Original paper

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide

Aleksandra Berkan-Kawińska
1
,
Anna Piekarska
1
,
Hanna Berak
2
,
Włodzimierz Mazur
3
,
Aleksander Garlicki
4
,
Magdalena Tudrujek-Zdunek
5
,
Beata Lorenc
6
,
Dorota Dybowska
7
,
Łukasz Socha
8
,
Anna Parfieniuk-Kowerda
9
,
Robert Flisiak
9

  1. Department of Infectious Diseases and Hepatology, Medical University of Lodz, Łódź, Poland
  2. Hospital for Infectious Diseases, Warsaw Medical University, Warsaw, Poland
  3. Clinical Department of Infectious Diseases, Medical University of Silesia, Chorzów, Poland
  4. Department of Infectious and Tropical Diseases, Collegium Medicum, Jagiellonian University, Kraków, Poland
  5. Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland
  6. Department of Infectious Diseases, Pomeranian Center of Infectious Diseases, Medical University of Gdansk, Gdańsk, Poland
  7. Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland
  8. Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University, Szczecin, Poland
  9. Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
Clin Exp HEPATOL 2024; 10, 3: 165-169
DOI: https://doi.org/10.5114/ceh.2024.141752
Online publish date: 2024/07/29
View full text Get citation
 
PlumX metrics:
Aim of the study:
To assess the real-life efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) in HIV/HCV-positive patients treated with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF).

Material and methods:
Patients were evaluated in terms of their baseline biochemical characteristics, which included platelet count, serum creatinine and bilirubin levels, alanine transaminase (ALT) activity, international normalized ratio (INR) and Model for End-Stage Liver Disease (MELD) score. The efficacy endpoint was the achievement of a sustained virologic response at posttreatment week 12 (SVR12), defined as undetectable HCV RNA 12 weeks after the scheduled end of therapy.

Results:
No significant differences in baseline patient characteristics between the two study groups were observed. Patients treated with sofosbuvir/velpatasvir (SOF/VEL) were more often treatment-naïve, but the difference was not statistically significant (96.0% vs. 86.8% in GLE/PIB group, p = 0.0629). Prevalence of genotype 3 was higher in the group treated with GLE/PIB (36.9% vs. 21.8% in SOF/VEL group, p = 0.183382), while genotype 1 was more frequent in patients treated with SOF/VEL (55.4% vs. 44.7% in GLE/PIB group, p = 0.348202), but again it did not prove to be statistically significant. SVR12 rates reached 78.9% and 80.2% for GLE/PIB and SOF/VEL, respectively, in ITT analysis, and 100% and 98.8%, respectively, in modified intent-to-treat (mITT) analysis.

Conclusions:
The study showed that real-life results of direct acting antiviral (DAA) therapy with GLE/PIB or SOF/VEL did not differ significantly in HIV/HCV-coinfected patients treated with B/FTC/TAF. Both regimens allowed encouraging SVR12 rates and treatment safety to be achieved, as well as tolerability, which was also comparable between the study groups.

keywords:

HIV/HCV coinfection, DAA treatment, glecaprevir/pibrentasvir, bictegravir/emtricitabine/tenofovir alafenamide
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.